In Brief:
Within a nonrandomized, prospective, and single-center clinical trial, 40 or 42 patients received a single-level treatment with the ProDisc C or ProDisc Vivo, respectively. The incidence of heterotopic ossification was significantly lower in the ProDisc Vivo group. Clinical parameters improved significantly over time in both groups.